Defense World
29 Mar 2026, 06:13 UTC · 27w ago
Verdict
Headline takes no side. We score WT +0.40 across five claims — moderately bullish.
+0.40moderately bullish
More positive than 64% of ticker scores this week
What the story claims
5 claims · scored −1 bearish … +1 bullish
Ironwood Pharmaceuticals trades at a higher price-to-earnings ratio than its peers, indicating it is currently more expensive than other companies in its industry.
So whatA premium valuation relative to peers with inferior fundamentals makes the stock vulnerable to multiple compression and institutional selling.
More negative than 91% of claims this week
Ironwood Pharmaceuticals has a consensus target price upside of 60.95%, which is lower than its industry peer group average upside of 76.65%.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More negative than 86% of claims this week
Ironwood Pharmaceuticals' peers generate higher revenue and earnings than Ironwood Pharmaceuticals.
More negative than 82% of claims this week
Ironwood Pharmaceuticals has a beta of 0.24, making its share price significantly more volatile than its peers' average beta of -0.52.
More negative than 70% of claims this week
Ironwood Pharmaceuticals' peers beat it on 7 of the 13 factors compared in the analysis.
More negative than 67% of claims this week
Which stocks this story touches
More positive than 64% of ticker scores this week
The company is listed as having a 'Moderate Buy' average recommendation from brokerages.
More positive than 64% of ticker scores this week
The company is listed as having a 'Moderate Buy' consensus recommendation from brokerages.
More negative than 71% of ticker scores this week
The company underperforms its peers in 7 of 13 key factors and is viewed as having less favorable growth aspects and higher valuation.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
2h ago
More positive than 74% of relationship scores this week
[mutual] Ironwood Pharmaceuticals has a strategic partnership with Astellas Pharma Inc. for the development and commercialization of linaclotide.
More positive than 74% of relationship scores this week
[mutual] Ironwood Pharmaceuticals has a strategic partnership with AbbVie Inc. for the development and commercialization of linaclotide.
+74.0%
Price agrees with the score
$24.18 vs $13.90 close before publication (Mar 27) · not market-adjusted
WT chart →
